Amphion Innovations (AMP)

 

AMP Share PerformanceMore

52 week high4.7000 21/04/17
52 week low1.2500 29/09/17
52 week change -1.2550 (-40.16%)
4 week volume29,014,364 24/09/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Related Party Transaction

RNS Number: 2529T Amphion Innovations PLC 11 October 2017 Amphion Innovations plc ("Amphion" or "the Company") Related Party Transaction Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, provides further details on the Deed of Postponement as announced on 29 September 2017 in the Company's inte...

Amphion partner releases positive clinical results

Amphion partner company Motif Bio has announced positive topline results for iclaprim in the REVIVE-2 phase 3 study. ...

Partner Company releases positive clinical results

RNS Number: 7464S Amphion Innovations PLC 05 October 2017 Amphion Innovations plc ("Amphion" or "the Company") Amphion Partner Company, Motif Bio, Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study Iclaprim met the primary endpoint Iclaprim was well tolerated in the study NDA submission expected in the first quarte...

Amphion revenues rise

Amphion Innovations' revenues rose to $153,000 in the six months to the end of June compared with US $60,000 last time. T...

Half-year Report

RNS Number: 1611S Amphion Innovations PLC 29 September 2017 29 September 2017 AMPHION INNOVATIONS PLC ("Amphion" or the "Company") Interim results for the six months to 30 June 2017 London and New York,29 September 2017 - Amphion Innovations plc (AIM: AMP),the developer of medical, life science, and technology businesses,announces its aud...

Holding(s) in Company

RNS Number: 6347R Motif Bio PLC 25 September 2017 25 September 2017 Motif Bio plc ("Motif" or the "Group") Holding(s) in the Company Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 22 September 2017 by Amphion Innovations plc ("Amphion") that a tot...

Sale of Partner Company Shares

RNS Number: 6345R Amphion Innovations PLC 25 September 2017 Amphion Innovations plc ("Amphion" or "the Company") Sale of Partner Company Shares London and New York: Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that 4,390,000 shares in Partner Company, Motif Bio have been sold...

Amphion reduces stake in Motif Bio

Amphion Innovations has soled 1,700,000 shares in partner company, Motif Bio, in partial repayment of the loan facility or...

Latest discussion posts More

  • Re: Expensive drawdown facility

    What to do? Sell or avoid? Have been watching this, but any upside to Motif will simply mean AMP selling stake to pay the debt/bills? Will any Motif windfall be squandered? ...
    15-Jul-2016
    bobsson
  • Re: Expensive drawdown facility

    Agree wholeheartedly! Conflicted company officers are electing, against their fiduciary duty, to unecessarily bleed our company dry when cheaper funding could clearly be ...
    13-Jul-2016
    nodebt
  • Expensive drawdown facility

    This facility seems very expensive $750,000 borrowed today and $881,000 having to be repaid in less than 4 months time and some of it being used to pay back a previous ...
    13-Jul-2016
    northumbrian-piper

Users' HoldingsMore

Users who hold Amphion Innovations also hold..
ASHLEY HOUSE20%
LLOYDS GRP.20%
MOTIF BIO20%
ROCKHOPPER16%
PRIMORUS INV.16%

Codes & Symbols

ISINGB00B0DJNP99
SymbolsAMP, LSE:AMP, AMP.L, AMP:LN, LON:AMP, XLON:AMP